A Japanese health ministry proposal to impose steeper price cuts on certain medicines deemed to carry poor cost-effectiveness profiles cleared…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Japan Clears Bill to Create Emergency Approval System, Enforcement Slated by Month-End
May 13, 2022
-
BUSINESS Shionogi Books 110 Billion Yen Sales for Yet-to-Be-Approved COVID Pill, Vaccine: FY2022 Outlook
May 12, 2022
-
BUSINESS Opdivo Projected to Grow 38% to 155 Billion Yen, but Ono Chief Sees No Re-Pricing
May 12, 2022
-
BUSINESS Jardiance Will Come Back as No. 1 in Japan SGLT2 Space after CKD Launch: NBI Chair
May 11, 2022
-
COMMENTARY Foreign Pharma Growing Vocal against Japan’s Pricing Policy, Flags Return of Drug Lag
May 10, 2022
-
ACADEMIA Difficult-to-Quantify Factors Should Be Reflected in Drug Prices to Establish VBP: Health Economist
May 9, 2022
-
REGULATORY Maruho’s Rozex in Line for Rosacea Nod in Japan
May 9, 2022
-
BUSINESS Astellas Logs 1st Sales Growth in 3 Years in FY2021; Chairman Hatanaka to Bow Out
April 28, 2022
-
REGULATORY Japan Panel OKs Second Booster for Age 60-Plus, and High-Risk Adults
April 28, 2022
-
REGULATORY Novavax COVID-19 Jab OK’ed for 1st to 3rd Shot Use under Free Program
April 28, 2022
-
ORGANIZATION JPMA Think Tank Analyzing Cause of Expanding Drug Lag, Over 70% of US/EU Approved Meds Not Available in Japan
April 27, 2022
-
BUSINESS Japan Drug Makers Revving Up HR, Pay System Reforms; Eisai Mulling No Daily Allowance for Sales Reps
April 27, 2022
-
BUSINESS Sumitomo Scraps Daily Allowance for Sales Reps, Introduces Division Bonus to Boost Productivity
April 26, 2022
-
BUSINESS Chugai’s Q1 Sales Double on Ronapreve Bonanza, Brisk Hemlibra Export
April 26, 2022
-
REGULATORY Japan Panel OKs Comirnaty, Spikevax for 4th Shot, Use Limited to High-Risk People
April 26, 2022
-
REGULATORY SCARDA Provost Confident about Japanese Technologies, Wants to Mediate Company Matching
April 25, 2022
-
BUSINESS MSD Japan’s Sales Surge 7.5% in 2021, 1.5% Growth If Lagevrio Excluded: President
April 22, 2022
-
BUSINESS GSK Japan Chief Has High Hopes for Shingrix, Blenrep, RSV Jab as Future Growth Drivers
April 21, 2022
-
BUSINESS Lumakras, Bimzelx, Pivlaz Now Available in Japan
April 21, 2022
-
BUSINESS Post-Azilva, Takeda Set to Morph into Rare Disease Specialty Pharma in Japan
April 20, 2022
ページ
A Japanese drug pricing panel on November 11 discussed ways to respond to the US most-favored-nation (MFN) policy, with healthcare…
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…